Disease · MONDO_0007650

MALT lymphoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. MALT lymphoma. Diseases, record MONDO_0007650. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007650

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: MALT lymphoma; Open Targets
Open Targets ID: MONDO_0007650; Open Targets
Other names: Extranodal marginal zone B-cell lymphoma, Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma), Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, Immunocytoma, MALToma, lymphoma of mucosa-associated lymphoid tissue, lymphoma, MALT, somatic, mucosa-associated lymphatic tissue lymphoma, mucosa-associated lymphoid tissue lymphoma; Open Targets
Disease Ontology: DOID:0050909; Disease Ontology
NCI Thesaurus: C3898; NCI Thesaurus
Orphanet: ORPHA:52417; Orphanet
Highest stage of its drugs: Phase 3, for 2 of its 26 drugs, from ClinicalTrials.gov; Open Targets

Drugs26

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RITUXIMAB	CHEMBL1201576	Antibody	Phase 3	ClinicalTrials.gov	14	14	14	Drugs and targets
CHLORAMBUCIL	CHEMBL515	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ORELABRUTINIB	CHEMBL4650321	Small molecule	Phase 2	ClinicalTrials.gov	6	6	6	Drugs and targets
LENALIDOMIDE	CHEMBL848	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
AMOXICILLIN	CHEMBL1082	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ARSENIC	CHEMBL1231052	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BENDAMUSTINE	CHEMBL487253	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BISMUTH SUBSALICYLATE	CHEMBL1120	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 26

See all 26 drugs

Targets72

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
MS4A1	B-lymphocyte antigen CD20	3	B-lymphocyte antigen CD20 binding agent	Phase 3	https://conductscience.org/library/genes/931	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	2	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/51185	Drugs and targets
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	2	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/8451	Drugs and targets
DDB1	CRL4(CRBN) E3 ubiquitin ligase	2	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/1642	Drugs and targets
RBX1	CRL4(CRBN) E3 ubiquitin ligase	2	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/9978	Drugs and targets
ADA	Adenosine deaminase	1	Adenosine deaminase inhibitor	Phase 2	https://conductscience.org/library/genes/100	Drugs and targets
ADRM1	26S proteasome	1	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/11047	Drugs and targets
ATP4A	Potassium-transporting ATPase	1	Potassium-transporting ATPase inhibitor	Phase 2	https://conductscience.org/library/genes/495	Drugs and targets
ATP4B	Potassium-transporting ATPase	1	Potassium-transporting ATPase inhibitor	Phase 2	https://conductscience.org/library/genes/496	Drugs and targets
BCL2	Apoptosis regulator Bcl-2	1	Apoptosis regulator Bcl-2 inhibitor	Phase 2	https://conductscience.org/library/genes/596	Drugs and targets

1 to 10 of 72

See all 72 targets

Trials26

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00210353	Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma	Phase 3	454	2019-06-06	Lymphoma, Mucosa-Associated Lymphoid Tissue	CHLORAMBUCIL, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00446095	Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma	Phase 1/2	81	2014-12-18	Lymphoma	FOSTAMATINIB	Its record names the disease	ClinicalTrials.gov
NCT01611259	Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue	Phase 2	50	2017-11-06	Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)	LENALIDOMIDE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00117156	Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma	Phase 2	26	2014-10-06	Lymphoma, Non-Hodgkin, MALT Lymphoma	FLUDARABINE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00387023	Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma	Not applicable	12	2013-11-18	Non-Hodgkin's Lymphoma, Lymphoma	RITUXIMAB, YTTRIUM Y 90 IBRITUMOMAB TIUXETAN	Its record names the disease	ClinicalTrials.gov
NCT00927797	Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)	Phase 2	185		Immunocytoma/Morbus Waldenström, B-Cell Non-Hodgkin's Lymphoma, B-Cell Chronic Lymphocytic Leukemia	CYCLOPHOSPHAMIDE, PENTOSTATIN, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT06228963	Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma	Phase 2	160		MALT Lymphoma of Stomach, Helicobacter Pylori Infection	ORELABRUTINIB	Its record names the disease	ClinicalTrials.gov
NCT03276468	Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas	Phase 2	136		Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue	ATEZOLIZUMAB, OBINUTUZUMAB, VENETOCLAX	Its record names the disease	ClinicalTrials.gov
NCT01808599	Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma	Phase 2	112		MALT Lymphoma	CHLORAMBUCIL, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT06064344	RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT Lymphoma	Not applicable	108		Primary Ocular Adnexal MALT Lymphoma	RITUXIMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 26

See all 26 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials12

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
27879257	RESULT	1	PubMed
19344412	RESULT	1	PubMed
39608989	DERIVED	1	PubMed
38385243	DERIVED	1	PubMed
37801707	DERIVED	1	PubMed
32182364	DERIVED	1	PubMed
28978139	DERIVED	1	PubMed
27029228	DERIVED	1	PubMed
23295789	DERIVED	1	PubMed
22899582	DERIVED	1	PubMed

1 to 10 of 12

See all 12 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0007650

GET https://conductscience.org/api/diseases/v1/MONDO_0007650/drugs?page=2

API reference For AI assistants